insights_auto
Kodėl „BT3“ sumažėjo 6,90%?
Įsigilintichevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
0,78 €
arrow_downward
−6,90%(−0,058) 1 D.
10-02, 08:01:10 GMT+2 · EUR
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „BT3“ įžvalgos...
Atidaryti
0,78 €
Aukšta
0,78 €
Žema
0,78 €
Rinkos kapitalizacija
235,20 mln.
Vid. kiekis
0,00
Apimtis
0,00
52 sav. aukšta
1,69 €
52 sav. žema
0,78 €
Darbuotojų skaičius
75
Atidaryti
0,78 €
Aukšta
0,78 €
Žema
0,78 €
Rinkos kapitalizacija
235,20 mln.
Vid. kiekis
0,00
Apimtis
0,00
52 sav. aukšta
1,69 €
52 sav. žema
0,78 €
Darbuotojų skaičius
75
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Kalkine Media
·
prieš 12 minučių
What Is Knowles (NYSE:KN) Adding to the NYSE RF Market?
ChartMill
·
prieš 59 minutes
What's going on in today's session: dow jones movers
Barron's
·
prieš 27 minutes
The Stock Market Is Splitting in Two. Why That’s an Opportunity for Investors.
Yahoo Finance
·
prieš 2 valandas
1 S&P 500 Stock to Research Further and 2 Facing Headwinds
Profilis
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Apie „Lineage Cell Therapeutics Inc“